[5] Observational studies provide additional context but face methodological challenges: patients prescribed GLP-1 receptor agonists typically have more advanced metabolic disease, higher body mass index, and greater baseline pancreatitis risk than comparison groups
Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight, said John Sharretts, MD, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research, via a press release
[9] Wegovy is available as a single-use injection pen in 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg strengths
This network connects the ventral tegmental area (VTA) to the nucleus accumbens and is responsible for the hit of pleasure you feel when eating something delicious, receiving good news, or critically consuming alcohol or other addictive substances
